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HIV Resistance Prediction using Feed Forward Neural Networks
and Sequence Expansion Methodologies

Abstract
HIV is a chronic and debilitating disease affecting the lives of
millions of people globally. While therapies to treat HIV are available,
drug resistance is a consistent problem. For this reason, an effective
means of determining drug resistance for a given isolate is needed. In this
experiment, we use a simple Artificial Neural Network (ANN) model
trained on phenotypically labeled sequences from HIVdb for resistance
classifications. We also observe an interesting data processing method,
and determine train and test set division before such data processing is
optimal for network performance.

2

Contents
Chapter 1: Introduction and Background

4

The HIV Virion and a History of Antiretrovirals

5

Resistance Classifiers and Related Works

6

Chapter 2: Methods

10

Sequence Acquisition and Processing

10

Sequence Expansion Algorithm

11

Network Structure, Training, and Testing

12

Chapter 3: Results

15

3TC

16

ABC

17

AZT

18

D4T

19

DDI

20

EFV

21

ETR

22

NVP

23

RPV

24

TDF

25

MultiDrug

26

One-Hot

27

Label Distribution

28

Chapter 4: Discussion
Effects of Expansion and Comparing Pre to Post Methods

29

How Our Work Compares

31

The MultiDrug Network and Ambiguity Distribution

33

Chapter 5: Concluding Remarks

34

Future Considerations

34

Acknowledgements

35

3

Chapter 1: Introduction
HIV is a pandemic disease which affects the lives of approximately
36 million people worldwide, annually killing 940,000 as of 2017. About
1.8 million of these cases are new. The Human Immunodeficiency Virus
(HIV) targets the host immune system, causing a decrease in defense
against infections and some cancers. If allowed to progress, Acquired
Immune Deficiency Syndrome (AIDS) can develop, with symptoms
including severe infections like tuberculosis, weight loss, fever, and
lymphomas. There is currently no known cure for HIV/AIDS, however a
number of treatment options do exist (WHO 2018). A recent case though
was reported cured through bone marrow transplants, and although the
incident is not fully understood nor yet fully applicable to general HIV
patients, it has sparked interest in new potentials for managing the
disease.
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1.

The HIV Virion and a History of
Antiretrovirals
The HIV virion itself is composed if 15 proteins categorized as

either structural, enzymatic, gene regulatory, or accessory. They are: MA ,
CA , NC , p6, SU , and TM , PR , RT , IN, Tat, Rev, Nef, Vif, Vpr, and Vpu.
All structural proteins include MA (matrix), CA (capsid), NC
(nucleocapsid), p6, SU (surface), and TM (transmembrane). All enzymatic
proteins include PR (protease), RT (reverse transcriptase), and IN
(integrase), and are of greatest interest here, as they are crucial in the HIV
life cycle, unique to the virus, and so are ideal for drug therapy. Most such
treatments target specific stages in the HIV life cycle driven by these
enzymatic proteins, namely reverse transcription, genome integration,
and protein assembly (NIH 2018). The four main classes of drugs used in
these treatments are nucleoside reverse transcriptase inhibitors (NRTI’s),
non-nucleoside reverse transcriptase inhibitors (NNRTI’s), protease
inhibitors (PI’s), and integrase inhibitors. The first of such drugs
developed was an NRTI called azidothymidine (AZT), discovered in 1964
by the National Cancer Institute and originally used in cancer therapy.
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Since then, a multitude of antiretrovirals (ARV’s) have been created, with
more than 30 drugs currently available, making treatment of HIV more
manageable and effective. However, HIV mutates quickly, allowing some
people to become resistant within a matter of days. To counter drug
resistance, a triple drug therapy called highly active antiretroviral therapy
(HAART) was developed, which combines multiple drug classes in a single
treatment, acting as a high genetic barrier to resistance (NIH 2019). Still,
due to the lack of proofreading by reverse transcriptase during viral
replication, high mutation rates can still generate resistant strains (Ji
1992). It is estimated that 8-20% of untreated carriers in North America
are to some degree drug resistant (WHO 2018). And so an efficient means
of resistance testing is needed for prescribing effective antiretrovirals,
given that current testing is both expensive and time consuming.
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2.

Resistance Classifiers and Related Works

A solution to efficient resistance testing is a genotypic
interpretation algorithm, such as Stanford’s HIVdb Program. Most
such algorithms though are rules based, using known mutation
sites along the HIV genome to determine likelihood of resistance.
For instance, a large class of mutations used in the HIVdb Program
for resistance in RT are Thymidine Analog Mutations (TAM’s).
TAM’s typically confer AZT and D4T resistance, and are classified
into two main types. Type 1 TAM’s include the mutations M41L,
L210W, and T215Y, while type 2 TAM’s include D67N, K70R,
T215F, and K219Q/E, with the main difference between these types
being that type 1 confers greater resistance to ABC, DDI, and TDF
compared to type 2. Another class called multi-nucleoside
mutations include the Q151M mutation which occurs in concert
with a number of accessory mutations: A62V, V75I, F77L, and
F116Y. By itself, this mutation can confer high level resistance to
AZT, D4T, DDI and ABC, but with accessories can confer additional
mid level resistance to 3TC, FTC and TDF (NRTI Resistance Notes).
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Other algorithms use classification methods such as Artificial
Neural Networks (ANN’s), Sparse Dictionary Classification,
Random Forest, and Support Vector Machines to make qualitative
predictions (Khalid 2018; Shen 2016; Yu 2014; Yu 2013) . A number
of these experiments have unique data processing methods, some
of which incorporate protein structural data. For instance, Yu et al.
2014 reported using Delaunay triangulation to encode 3D residue
position. Khalid et al. incorporated hydrophobicity data and
protein secondary structure into support vector machines. In this
experiment we apply a simple ANN model, while also
implementing a data processing method, which uses sequence
expansion to handle data ambiguity. This data processing method
has been used in a number of studies with reportedly good results,
and for this reason we wanted to explore certain characteristics
(Amamudy 2018; Yu 2014; Yu 2013). In Yu 2014, initial sequences
for HIV Reverse Transcriptase (RT), and HIV Protease (PR) were
acquired from Stanford’s HIVdb and then expanded using the
above mentioned algorithm, producing approximately 60,000 total
sequences. Each sequence had a set of drug resistant labels, which
were encoded such that for a given PR sequence, a label value < 3.0
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was denoted as 0, and a value > 3.0 was denoted as 1, while RT
cut-off values varied according to the drug. Amino acids for a
particular sequence were then encoded into an adjacency matrix
using Delaunay triangulation, where each entry is the average
distance between two types of amino acids based on the typical
protein structure. While reports from this work indicate good
performance, we note that the Delaunay triangulation may overly
compress protein structure data and so format things in a way that
is less biologically significant.
Amammudy also implements the expansion algorithm for
RT and PR data, though with some slight modifications. Before
expansion, they removed non B subtypes from the data set, and
then performed the expansion with set cut-off values, meaning
that sequences were limited in the number of expanded sequences
they could create. They then encoded the amino acids with an
integer value of 1 to 22. Neural networks with various architectures
were made to train on different drug labels from the expanded
data, and networks with the best performance were chosen. We
note a number of potential issues here as well. Firstly, the amino
acid encoding method used implies higher similarity between
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certain residues when compared to others, which is not necessarily
true. Secondly, choosing of arbitrary and variant architures for
each drug label is not best practice, especially when the specific
architectures chosen for each label are not indicated.
Due to these exceptional results, despite our skepticism
about several algorithmic choices, we attempted to replicate the
methods used in Amammudy and evaluate the impact of some of
their analysis choices. Particularly, we tested the effects of
expansion generally on network performances, and attempted to
characterize the importance of dividing training and test sets
either before or after applying the sequence expansion method.

Chapter 2: Materials and Methods
1.

Sequence Acquisition and Processing
1916 PhenoSense RT sequences were acquired from Stanford’s
HIVdb. Each sequence entry contained the list of mutated amino
acid positions for an isolate, as well as the degree of drug
resistance for a set drug list. The degree of resistance for each drug
was experimentally determined using Viralogic’s Phenosense
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assay, with a value greater than 1 indicating above standard
resistance. The drug set was a combination of NRTI’s and NNRTI’s:
3TC, ABC, AZT, D4T, DDI, TDF, EFV, NVP, ETR, and RPV. In order
to better understand the data, we performed an analysis of subtype
distribution, and found that subtype B was most prevalent.
Accordingly, we subtracted non subtype B entries from the data set
to eliminate possible noise. The data was then parsed, with the
sequence data placed inside of our input tensor, and the resistance
data inside of our target. The data sets were then encoded for
proper input into the network. For each entry in the sequence data,
the amino acids were converted to a sequence of integers, where
each amino acid is represented by a number from 1 to 22, and the
total length of the sequence is set to the length of HIVdb’s RT
consensus sequence. The target is converted to a sequence of 0’s
and 1’s, where 1 indicates the degree of resistivity reported for a
drug is greater than 1, and 0 indicates a resistivity <= 1.
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2.

Sequence Expansion Algorithm
Next, we implemented the sequence expansion algorithm. Due to
the method of sequence recording and natural diversity of HIV in
samples, there are ambiguous sites along a sequence, usually
represented as either an X or a combination of amino acids (AA’s)
separated by a comma. An ‘X’ here means that the site was not
recorded, and multiple AA’s mean that several residues were
recorded. For instance, if we consider ‘X’ to be any amino acid, a
single ambiguous sequence with an X can represent 22 possible
real sequences. For each sequence then, we calculated the number
of possible sequences which could be derived from ambiguous
sites. Then, if the number of possible sequences for an expansion
exceeded a cut-off value, we removed that sequence from the data.
To understand the effects of the cut-off on model performance, we
attempted three different cut-off values of 1000, 300, and 50,
generating three unique data sets. After expansion, we recorded
64,000, 37,000 , and 11,000 sequences total in each set, and also
counted negative to positive labels for each drug in each set to
monitor effects of expansion on data balance.
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3.

Network Structure, Training, and Testing
Next, we constructed 11 simple feed forward neural networks, each
with 1 hidden layer of 20 nodes using Pytorch. We chose the built
in Multi Label Margin Loss as our loss function, and set the
learning rate at 1e-4. We then trained each of the 11 networks
differently. One of the networks was trained using the entire input
and target, which we termed the MultiDrug network. The other 10
networks were trained using only a subset of the target, so that the
target was a single value representing resistivity for a single drug.
Each network then specialized in the prediction of a single drug,
which we labeled Single Drug networks. Before training, we divided
the input data into train and test sets, with the division being 70%
to 30%. We then trained and tested all networks for 10 epochs,
recording accuracy, precision, fallout, and recall, with a cutoff for
true predictions at 0.7. After training and testing, AUC (Area Under
the ROC Curve) curves were generated for each network.
Training and testing sets were then generated using two
different methods, specifically pre-expansion and post expansion.
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Out of curiosity in exploring the methods used in Amamudy 2018,
we wished to observe the effects of dividing our data set at these
distinct points. 70% to 30% train and test sets were then generated
before expansions, and then expanded independently, while a
separate train and test set were derived from the initial data after
expansion. We then encoded, and passed these sequences into 11
networks for training and testing in the same way as described
previously for our post expansion set, and then again for the
pre-expansion set for each of the three expanded sets.
We also trained and tested in the absence of expansion
using “one-hot” encoding. We did this in an attempt to determine
the potential effects of this encoding technique on network
performance.
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Chapter 3: Results
We created AUC curves for each drug, or rather for each Single Drug
network at three distinct values for expansion cut off and at two points
before and after we expanded. We did this to measure network
performance in conjunction with the expansion, and to provide insight
into when expansion should be occurring.
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1.

3TC

Figure 1: 3TC Single Drug Networks Pre Expansion for Train (Blue), and
Test (Green) at cut-off values of 50, 300, and 1000 going from left to right.

Figure 2: 3TC Single Drug Networks Post Expansion for Train (Blue), and
Test (Green) at cut-off values of 50, 300, and 1000 going from left to right.
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2.

ABC

Figure 3: ABC SingleDrug Networks Pre Expansion for Train (Blue), and
Test (Green) at cut-off values of 50, 300, and 1000 going from left to right.

Figure 4: ABC SingleDrug Networks Post Expansion for Train (Blue), and
Test (Green) at cut-off values of 50, 300, and 1000 going from left to right.
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3.

AZT

Figure 5: AZT SingleDrug Networks Pre Expansion for Train (Blue), and
Test (Green) at cut-off values of 50, 300, and 1000 going from left to right.

Figure 6: AZT SingleDrug Networks Post Expansion for Train (Blue), and
Test (Green) at cut-off values of 50, 300, and 1000 going from left to right.
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4.

D4T

Figure 7: D4T SingleDrug Networks Pre Expansion for Train (Blue), and
Test (Green) at cut-off values of 50, 300, and 1000 going from left to right.

Figure 8: D4T SingleDrug Networks Post Expansion for Train (Blue), and
Test (Green) at cut-off values of 50, 300, and 1000 going from left to right.
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5.

DDI

Figure 9: DDI SingleDrug Networks Pre Expansion for Train (Blue), and
Test (Green) at cut-off values of 50, 300, and 1000 going from left to right.

Figure 10: DDI SingleDrug Networks Post Expansion for Train (Blue), and
Test (Green) at cut-off values of 50, 300, and 1000 going from left to right.
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6.

EFV

Figure 11: EFV SingleDrug Networks Pre Expansion for Train (Blue), and
Test (Green) at cut-off values of 50, 300, and 1000 going from left to right.

Figure 12: EFV SingleDrug Networks Post Expansion for Train (Blue), and
Test (Green) at cut-off values of 50, 300, and 1000 going from left to right.
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7.

ETR

Figure 13: ETR Single Drug Networks Pre Expansion for Train (Blue), and
Test (Green) at cut-off values of 50, 300, and 1000 going from left to right.

Figure 14: ETR Single Drug Networks Post Expansion for Train (Blue),
and Test (Green) at cut-off values of 50, 300, and 1000 going from left to
right.
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8.

NVP

Figure 15: NVP Single Drug Networks Pre Expansion for Train (Blue), and
Test (Green) at cut-off values of 50, 300, and 1000 going from left to right.

Figure 16: NVP Single Drug Networks Post Expansion for Train (Blue),
and Test (Green) at cut-off values of 50, 300, and 1000 going from left to
right.
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9.

RPV

Figure 17: RPV Single Drug Networks Pre Expansion for Train (Blue), and
Test (Green) at cut-off values of 50, 300, and 1000 going from left to right.

Figure 18: RPV Single Drug Networks Post Expansion for Train (Blue),
and Test (Green) at cut-off values of 50, 300, and 1000 going from left to
right.
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10. TDF

Figure 19: TDF Single Drug Networks Pre Expansion for Train (Blue), and
Test (Green) at cut-off values of 50, 300, and 1000 going from left to right.

Figure 20: TDF Single Drug Networks Post Expansion for Train (Blue),
and Test (Green) at cut-off values of 50, 300, and 1000 going from left to
right.

25

11. MultiDrug

Figure 21: MultiDrug Networks Pre Expansion for Train (Blue), and Test
(Green) at cut-off values of 50, 300, and 1000 going from left to right.

Figure 22: MultiDrug Networks Post Expansion for Train (Blue), and Test
(Green) at cut-off values of 50, 300, and 1000 going from left to right.
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12. One-Hot
TDF

RPV

EFV

DDI

NPV

ETR

D4T

AZT

ABC

3TC

Mult

Figure 23: AUC’s for Single Drug and Multi Drug networks using one-hot
encoding without expansion during training.
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13. Label Distribution

A.

B.

C.

D.

Figure 24: The number of negative and positive labeled samples for each
drug at (A). Expansion cut-off=0, (B)Expansion cut-off=50, (C) Expansion
cut-off=300, (D) Expansion cut-off=1000.
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Chapter 4: Discussion
We wished to elucidate qualities of this expansion technique as it
relates to classification algorithms for antiretroviral resistance generally.
Given that the technique has become more widely used, it is import to
further explore characteristics peculiar to the method.

1.

Effects of Expansion and Comparing Pre to
Post Methods
Firstly, we note that across all Single Drug networks, an increase in
expansion cut-off value seems to optimize network performance.
This holds true for training, test, post expansion, and pre
expansion sets, indicating that the technique successfully improves
unsupervised learning. Importantly, between most train and test
AUC’s, there was minimal change in curve structure, indicating
that overfitting is minimized. However, in Single Drug groups DDI,
RPV, TDF, NPV, ETR, and EFV we observe a noticeable shift and
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occasional flattening of AUC’s in pre expansion test sets when
compared to training set counterparts (Figures 9, 11, 13, 15, 17,
19). The corresponding AUC’s in post expansion sets though
maintained their structure between train and tests sets (Figures 10,
12, 14, 16, 18, 20 ). This initially suggests that only pre expansion
sets observed overfitting. However given that both pre and post
expansion groups are trained and tested on the same data, we
think this result is indicative of a fault in post expansion methods.
Specifically, in high expansion cut-off groups, up to 1000 samples
are derived from a single entry, producing high sequence similarity
in the data set. The subsequent post expansion train and test sets
derived then likely have high similarity, producing tests that are
then not distinct from training, appearing to perform well, but are
considerably invalid. Pre expansion train and test set division is
then the optimal approach when using this technique.
Despite potentially exaggerated test performance in post
expansion sets, pre expansions sets performed as well or better
than post expansion sets for all drugs except ETR (Figures 13, 14).
While we are uncertain why ETR’s performance was notably lower,
it may be attributable to a lack of ETR resistant samples in the data
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set (Figure 24). Though, RPV has a similar deficit in resistant
samples and yet performs well, suggesting another factor is
involved. RPV actually performs well regardless of expansion
cut-off, and appears to outperform RPV post expansion across all
expansion cut-offs. We are unsure what may be causing RPV to
perform so well, but a lack of resistant samples (Figure 24) may
cause the model to always label negative, creating the appearance
of learning. Though, this still does not explain RPV post
expansion’s relatively poorer performance, and in light of ETR’s
similar condition, it may be another factor altogether.

2.

How Our Work Compares
In comparison to our results with those of Amammudy, we see that
we were not able to fully recreate their results, and that in general,
our networks performed substantially worse across all drugs. For
all NRTI’s and NNRTI’s, Amamudy reported test r-squared values
greater than 0.91, which is better than even the best of our Single
Drug networks. While we note that AUC’s are not equivalent to
r-squared values, we would still expect graphs with areas
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approaching 1. Given that we had mostly replicated their design,
we can attribute this difference in results to two likely sources.
First, we anticipate that Amammudy is likely performing the post
expansion technique, as they do not indicate any distinction
between pre and post techniques, and so the ordering of their
methods implies that the post expansion method was used. Doing
this could potentially over inflate test performance and so skew
their results. But even our post expansion sets could not generate
comparative results, and so we believe there to be another
potential cause. This cause may be the use of a variety of unique
network architectures for each Single Drug network. The use of
these unique architectures likely optimized performance further,
though as stated previously doing this is not considered best
practice, and is certainly not easily replicable as the final unique
architectures were not indicated. In Yu 2014, accuracies greater
than 91% were reported using an ANN model. However, it appears
that they may also be using the post expansion technique, though
their exact neural architecture is not well discussed, making
comparison limited.
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3.

The MultiDrug Network and Ambiguity
Distribution
The MultiDrug networks performed poorly across all groups
(Figures 21, 22). The change in expansion cut-off has no apparent
trend across train or test sets in either post expansion or pre
expansion. This result confirms that of Amamudy et al., and
assures us that our model is comparable.
We also tracked the quantity of negative and positive labels for
each drug across expansion cut-off as a way of determining the
effects of expansion on data balance (Figure 24). In particular, our
concern was that ambiguous sequences were distributed
disproportionately in the data, such that there were more
ambiguous sequences labeled negative or positive for a drug,
resulting in unbalanced data after expansion. However, drug
labeling balance appears mostly constant across expansions. This
indicates that the initial data set is more diverse and well
distributed with ambiguous sequences than originally expected.
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Chapter 5: Concluding Remarks
1.

Future Considerations
We had here explored a very specific quality of a certain algorithm
used in HIV resistance prediction. In future endeavors, however,
we would like to explore other routes of intrigue. Of particular
interest is the encoding of protein structural and chemical data
into classifiers. A number of authors here mentioned and also not
mentioned have reported successful use of such data in classifiers,
and so research into these classifiers to optimize network
performance may be an avenue. We have also discussed other
means of amino acid residue encoding which may confer more
detailed information to a classifier, especially in the case of
hydrophobicity and charge. A means of further characterizing the
expansion method is still needed also. Creating a sort of expansion
profile for a given data set which can indicate the degree of
expansion possible for each individual original sequence may be
useful in determining if the algorithm is a good fit for that data set.
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